Influenza virus hemagglutinin stalk-based antibodies and vaccines.

Antibodies against the conserved stalk domain of the hemagglutinin are currently being discussed as promising therapeutic tools against influenza virus infections. Because of the conservation of the stalk domain these antibodies are able to broadly neutralize a wide spectrum of influenza virus strains and subtypes. Broadly protective vaccine candidates based on the epitopes of these antibodies, for example, chimeric and headless hemagglutinin structures, are currently under development and show promising results in animals models. These candidates could be developed into universal influenza virus vaccines that protect from infection with drifted seasonal as well as novel pandemic influenza virus strains therefore obviating the need for annual vaccination, and enhancing our pandemic preparedness.

[1]  C. Gerdil.  The annual production cycle for influenza vaccine. , 2003, Vaccine.

[2]  J. Whittle,et al.  Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies , 2013, Nature.

[3]  K. Subbarao,et al.  B Cell Response and Hemagglutinin Stalk-Reactive Antibody Production in Different Age Cohorts following 2009 H1N1 Influenza Virus Vaccination , 2013, Clinical and Vaccine Immunology.

[4]  R. Varadarajan,et al.  Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge , 2010, Proceedings of the National Academy of Sciences.

[5]  P. Palese,et al.  Why Do Influenza Virus Subtypes Die Out? A Hypothesis , 2011, mBio.

[6]  S. Wharton,et al.  A monoclonal antibody specific to the HA2 glycoprotein of influenza A virus hemagglutinin that inhibits its fusion activity reduces replication of the virus. , 2003, Acta virologica.

[7]  F. Kostolanský,et al.  Antibodies induced by the HA2 glycopolypeptide of influenza virus haemagglutinin improve recovery from influenza A virus infection. , 2008, The Journal of general virology.

[8]  M. Meltzer,et al.  Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. , 2000, JAMA.

[9]  T. Uyeki,et al.  Neuraminidase H275Y and hemagglutinin D222G mutations in a fatal case of 2009 pandemic influenza A (H1N1) virus infection , 2012, Influenza and other respiratory viruses.

[10]  K. Nichol,et al.  Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: data from 3 health plans. , 2001, The Journal of infectious diseases.

[11]  D. Ekiert,et al.  Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes , 2010, Proceedings of the National Academy of Sciences.

[12]  T. Friedrich,et al.  Antibody-Dependent Cellular Cytotoxicity Is Associated with Control of Pandemic H1N1 Influenza Virus Infection of Macaques , 2013, Journal of Virology.

[13]  K. Subbarao,et al.  Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. , 2010, The Journal of clinical investigation.

[14]  Damian C. Ekiert,et al.  Structure of a Classical Broadly Neutralizing Stem Antibody in Complex with a Pandemic H2 Influenza Virus Hemagglutinin , 2013, Journal of Virology.

[15]  C. Boucher,et al.  Case report: Oseltamivir‐induced resistant pandemic influenza A (H1N1) Virus infection in a patient with AIDS and Pneumocystis jirovecii pneumonia , 2013, Journal of medical virology.

[16]  F. Kostolanský,et al.  Broadly cross-reactive monoclonal antibodies against HA2 glycopeptide of Influenza A virus hemagglutinin of H3 subtype reduce replication of influenza A viruses of human and avian origin. , 2009, Acta virologica.

[17]  A. Osterhaus,et al.  Prolonged Influenza Virus Shedding and Emergence of Antiviral Resistance in Immunocompromised Patients and Ferrets , 2013, PLoS pathogens.

[18]  G. Nabel,et al.  Induction of Broadly Neutralizing H1N1 Influenza Antibodies by Vaccination , 2010, Science.

[19]  N. S. Laursen,et al.  Highly Conserved Protective Epitopes on Influenza B Viruses , 2012, Science.

[20]  Matthew S. Miller,et al.  1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans. , 2013, The Journal of infectious diseases.

[21]  Adolfo García-Sastre,et al.  Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses , 2012, Proceedings of the National Academy of Sciences.

[22]  Boguslaw Stec,et al.  Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses , 2009, Nature Structural &Molecular Biology.

[23]  T. Kepler,et al.  H3N2 Influenza Infection Elicits More Cross-Reactive and Less Clonally Expanded Anti-Hemagglutinin Antibodies Than Influenza Vaccination , 2011, PloS one.

[24]  R. Hai,et al.  Chimeric Hemagglutinin Influenza Virus Vaccine Constructs Elicit Broadly Protective Stalk-Specific Antibodies , 2013, Journal of Virology.

[25]  John Steel,et al.  Influenza Virus Vaccine Based on the Conserved Hemagglutinin Stalk Domain , 2010, mBio.

[26]  F. Ennis,et al.  Complement-Dependent Lysis of Influenza A Virus-Infected Cells by Broadly Cross-Reactive Human Monoclonal Antibodies , 2011, Journal of Virology.

[27]  Gira Bhabha,et al.  Antibody Recognition of a Highly Conserved Influenza Virus Epitope , 2009, Science.

[28]  J. Skehel,et al.  A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins , 2011, Science.

[29]  G. Sapiro,et al.  Structure and accessibility of HA trimers on intact 2009 H1N1 pandemic influenza virus to stem region-specific neutralizing antibodies , 2013, Proceedings of the National Academy of Sciences.

[30]  K. Ikuta,et al.  Human Monoclonal Antibodies Broadly Neutralizing against Influenza B Virus , 2013, PLoS pathogens.

[31]  J. Crowe,et al.  A Broadly Neutralizing Human Monoclonal Antibody That Recognizes a Conserved, Novel Epitope on the Globular Head of the Influenza H1N1 Virus Hemagglutinin , 2011, Journal of Virology.

[32]  L. Simonsen,et al.  Surveillance and impact of influenza in the United States. , 1999, Vaccine.

[33]  A. Kelso,et al.  Progressive emergence of an oseltamivir‐resistant A(H3N2) virus over two courses of oseltamivir treatment in an immunocompromised paediatric patient , 2013, Influenza and other respiratory viruses.

[34]  Jens C. Krause,et al.  A Carboxy-Terminal Trimerization Domain Stabilizes Conformational Epitopes on the Stalk Domain of Soluble Recombinant Hemagglutinin Substrates , 2012, PloS one.

[35]  A. Shetty,et al.  Oseltamivir‐resistant 2009 H1N1 influenza pneumonia during therapy in a renal transplant recipient , 2012, Pediatric transplantation.

[36]  K. Laurie,et al.  Cross-Reactive Influenza-Specific Antibody-Dependent Cellular Cytotoxicity Antibodies in the Absence of Neutralizing Antibodies , 2013, The Journal of Immunology.

[37]  Martin H. Koldijk,et al.  A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses , 2011, Science.

[38]  J. Yewdell,et al.  Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection , 2011, The Journal of experimental medicine.

[39]  Jie Dong,et al.  Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus. , 2018 .

[40]  R. Albrecht,et al.  Influenza Viruses Expressing Chimeric Hemagglutinins: Globular Head and Stalk Domains Derived from Different Subtypes , 2012, Journal of Virology.

[41]  J. Young,et al.  Preparation of influenza virus subviral particles lacking the HA1 subunit of hemagglutinin: unmasking of cross-reactive HA2 determinants. , 1983, Virology.

[42]  Y. Guan,et al.  Heterosubtypic Neutralizing Monoclonal Antibodies Cross-Protective against H5N1 and H1N1 Recovered from Human IgM+ Memory B Cells , 2008, PloS one.

[43]  C. Cerini,et al.  Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees. , 1987, Journal of immunology.

[44]  A. Osterhaus,et al.  Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine‐induced antibody response to this strain in the elderly , 2000, Journal of medical virology.

[45]  H. Ohno,et al.  Outbreak of pandemic 2009 influenza A/H1N1 infection in the hematology ward: fatal clinical outcome of hematopoietic stem cell transplant recipients and emergence of the H275Y neuraminidase mutation , 2012, International Journal of Hematology.

[46]  R. Hai,et al.  Hemagglutinin Stalk-Reactive Antibodies Are Boosted following Sequential Infection with Seasonal and Pandemic H1N1 Influenza Virus in Mice , 2012, Journal of Virology.

[47]  F. Kostolanský,et al.  Antibodies induced by the HA 2 glycopolypeptide of influenza virus haemagglutinin improve recovery from influenza A virus infection , 2008 .

[48]  J. Whittle,et al.  Elicitation of Broadly Neutralizing Influenza Antibodies in Animals with Previous Influenza Exposure , 2012, Science Translational Medicine.

[49]  R. Hai,et al.  Broadly Protective Monoclonal Antibodies against H3 Influenza Viruses following Sequential Immunization with Different Hemagglutinins , 2010, PLoS pathogens.

[50]  A. Monto,et al.  Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. , 2011, The Journal of infectious diseases.

[51]  Mark Mulligan,et al.  Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells , 2012, Proceedings of the National Academy of Sciences.

[52]  A. Trkola,et al.  Complement Lysis Activity in Autologous Plasma Is Associated with Lower Viral Loads during the Acute Phase of HIV-1 Infection , 2006, PLoS medicine.

[53]  J. W. Schrader,et al.  Pandemic H1N1 Influenza Infection and Vaccination in Humans Induces Cross-Protective Antibodies that Target the Hemagglutinin Stem , 2012, Front. Immun..

[54]  S. Reed,et al.  Development of a high density hemagglutinin protein microarray to determine the breadth of influenza antibody responses. , 2013, BioTechniques.

[55]  Keiji Fukuda,et al.  Influenza-associated deaths among children in the United States, 2003-2004. , 2005, The New England journal of medicine.

[56]  Y. Isegawa,et al.  A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains , 1993, Journal of virology.

[57]  Patrick C. Wilson,et al.  Rapid cloning of high-affinity human monoclonal antibodies against influenza virus , 2008, Nature.

[58]  Martin H. Koldijk,et al.  New Class of Monoclonal Antibodies against Severe Influenza: Prophylactic and Therapeutic Efficacy in Ferrets , 2010, PloS one.

[59]  N. Heaton,et al.  Hemagglutinin Stalk-Based Universal Vaccine Constructs Protect against Group 2 Influenza A Viruses , 2013, Journal of Virology.

[60]  J. Kwang,et al.  Monoclonal Antibodies against the Fusion Peptide of Hemagglutinin Protect Mice from Lethal Influenza A Virus H5N1 Infection , 2008, Journal of Virology.

[61]  John Steel,et al.  Live Attenuated Influenza Viruses Containing NS1 Truncations as Vaccine Candidates against H5N1 Highly Pathogenic Avian Influenza , 2008, Journal of Virology.

[62]  Florian Krammer,et al.  Neutralizing Antibodies Against Previously Encountered Influenza Virus Strains Increase over Time: A Longitudinal Analysis , 2013, Science Translational Medicine.

[63]  I. Wilson,et al.  A Virus-Like Particle That Elicits Cross-Reactive Antibodies to the Conserved Stem of Influenza Virus Hemagglutinin , 2012, Journal of Virology.

[64]  G. Van Domselaar,et al.  Universal antibodies against the highly conserved influenza fusion peptide cross-neutralize several subtypes of influenza A virus. , 2010, Biochemical and biophysical research communications.

[65]  M. Peiris,et al.  Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance , 2013, The Lancet.

[66]  P. Palese,et al.  A Pan-H1 Anti-Hemagglutinin Monoclonal Antibody with Potent Broad-Spectrum Efficacy In Vivo , 2012, Journal of Virology.

[67]  John J. Treanor,et al.  H3N2 Influenza Virus Infection Induces Broadly Reactive Hemagglutinin Stalk Antibodies in Humans and Mice , 2013, Journal of Virology.